• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    New compounds which have the general formula <IMAGE> are useful as hypotensive agents.
    公开号:SU860697A1
    申请号:SU792729300
    申请日:1979-02-14
    公开日:1981-08-30
    发明作者:Анджел Ондетти Мигуел；Айер Натараджан Сеша
    申请人:Е.Р.Сквибб Энд Санз Инк. (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD FOR PRODUCING DERIVATIVES
    DEHYDROCYCLIC IMINO ACIDS
    one
    The invention relates to a process for the preparation of new derivatives of dehydrocyclic imino acids, which can be used in the chemical and pharmaceutical industry.
    A known method for the preparation of imines by the interaction of carbonic acids with secondary amines fl. The purpose of the invention is to develop, on the basis of a known method, a method of obtaining new compounds with the property of reducing blood pressure.
    The goal is achieved by the method of obtaining derivatives of dehydrocyclic imino acids of general formula
    H I C
    Hjc
    Cg I K1 - $ - (CHg) p-CH-C-1. (CHg) t
    o I; COOR
     each of the groups R and R 2 represents a hydrogen atom or a lower alkyl; R is a hydrogen atom, a lower alkaiyl,
    type is equal to O or 1, consisting in the fact that the compound of the formula
    R,
    II
    Rt-S- (CHz n-CH-COOH
    where R is a lower alkanonl, is subjected to interaction with the compound of the general forum
    ten
    H
    I
    III
    one
    CjftCHzU HNv
    one
    COOR
    where the R values are given above,
    in the presence of carbodiimide, for example
    20 dicyclohexylcarbodiimide; or an acid halide or acid anhydride of general formula II is reacted with a compound of general formula III, and the obtained desired product
    25 is either isolated or hydrolyzed, and the target product, in which R is a hydrogen atom, is isolated.
    Preferred are compounds of the formula D, in which the groups
    权利要求:
    Claims (2)
    [1]
    30 R and R2 are each hydrogen or lower C-C-alkyl, especially hydrogen or methyl; R. is hydrogen or lower C-C-y-alkanoyl, especially hydrogen or acetyl; m is O or 1, preferably O, and n is O or 1, preferably 1. The levorotatory form of the said cyclic imino acid is most acceptable. The compounds of general formula I have one asymmetric carbon atom, and in case Rg has a different meaning than hydrogen, two asymmetric carbon atoms. These compounds exist respectively in stereoisomeric forms or in the form of their racemic mixtures. The proposed compounds are used as hypotonic (by lowering blood pressure) agents. They inhibit the conversion of decapeptide-induced angiotensin I to angiotensin II and, therefore, are used to reduce or annihilate angiotensin, which is associated with increased blood pressure. The action of the enzyme renin on angiotensinogen, pseudoglobulin in the blood plasma, leads to the formation of angiotensin I. Angiotensin I under the action of an enzyme that causes angiotensin conversion (ACE) is converted into angiotensin II. The latter is an active, causing blood pressure substance, which is considered an excitatory agent in various forms of hypertension in various animal species, such as rats and dogs. The proposed compounds interfere with the transformation carried out in the sequence: angiotensinogen - (renin) - angiotensin I - (ACE) -JT angiotensin It, by inhibiting an enzyme that causes angiotensin conversion, and lowering or completely preventing blood formation that increases angiotensin pressure It. Thus, as a result of the introduction into the body of a composition containing one compound or a combination of compounds of formula I or a physiologically acceptable salt of the proposed compound, there is a decrease in high blood pressure caused by angiotensin in mammalian hypertension. The compound of general formula I is administered and the organism can preferably be used roently and enteric means of administration of the drug, as subcutaneous, intracellular, intravenous or intraoral. The proposed compounds can be used to lower the blood pressure of the legs by preparing the compositions in the form of tablets, capsules or elixirs suitable for oral administration, or in the form of sterile solutions or suspensions suitable for parenteral administration. A compound or mixture of compounds I or a physiologically acceptable salt of this compound in an amount of from about 10 to 500 mg is mixed with a physiologically acceptable solvent, carrier, excipient, binder, antioxidant, stabilizer, aromatic (or flavoring) seasoning in pharmaceutical practice. The amount of active substance in these compositions or preparations should be such that the appropriate dose is provided within the above ranges. Example 1. Methyl ester of 1- (3-acetylthiopropanoyl) -0,1-3,4-dihydroproline. 0.1-3.4j-dehydroproline methyl ester (3.75 g) is dissolved in dichloromethane (40 ml), the solution is cooled in an ice-water bath, and a solution of dicyclohexylcarbodiimide (6.18 g) in dichloromethane ( 21 ml), after which 3-acetylthiopropanoic acid (4.45 g) is immediately added. After a 15-minute stirring in an ice-water bath and holding for 16 hours at ksmni temperature, the precipitate is filtered off and the filtrate is evaporated to dryness in vacuo. The product obtained is dissolved in ethyl acetate and washed until neutral. The organic layer is dried over magnesium sulfate, evaporated to dryness and methyl 1- (3-acetylthiopropanoyl) -D, L-3,4-dehydroproline is obtained. Example 2. 1- (3-Mercaptopropanoyl) -O, L-3,4-dehydroprolin. Methyl 1- (3-acetylthiopropanoyl) -O, 1-3,4-dehydroproline methyl ester (2.5 g) is dissolved in a mixture of methanol (10 ml) and 1N. sodium hydroxide solution (20 ml). The mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours, diluted with water and extracted with ethyl acetate. The aqueous layer is acidified and extracted with ethyl acetate. The organic layer is dried over magnesium sulfate and evaporated to dryness, yielding 1- (3-mercaptopropanoyl) -D, 1-3,4-dehydropro LIND with a board temperature of 160163 s and 143 ° C sintering in the form of dicyclohexylene salt. R 0.33 purification is carried out by prodding through silica gel and elution with a solvent system: ethyl acetate-pyridine-acetic acid-water in a ratio of 45: 20: 6: 11. Example 3. 1-C3-Atstsh1ui 1. propanoyl) -O, 1-3,4-dehydroproline. 3-Acetylthiopropanoyl (5 g) and 2N. A solution of sodium hydroxide (15 ml) is added to a solution of 0, L-3, 4-degdroproline (3.4 g) in 1N. sodium hydroxide solution (30 ml) cooled in an ice-water bath. After stirring for 3 hours at room temperature, the mixture is extracted with ether, the aqueous phase is acidified and extracted with ethyl acetate. The organic layer is dried over magnesium sulphate and evaporated to dryness, as a result of which 1- (3-acetylthiopropanoyl) -O, L-3, 4-dehydroproline dicyclohexylamine salt is melted with a melting point of ISG-ISS C. (sintering). R 0.38; the product is purified by passing through silica gel and elution with a solvent system: ethyl acetate - pyridine - acetic acid - water in a ratio of 45: 20: 6: 11. Example 4. 2-Ethyl-3-acetylthiopropanoic acid. Thioacetic acid (6.61 g), ethyl acrylic acid (g) and several crystals of 2,2-azo-bis- (2-methylpropionitrile) are heated under reflux for 4 hours, the mixture is kept at room temperature for 48 hours, then evaporated to dryness, the residue after evaporation is again distilled twice with toluene. Yield 7.88 g of 2-ethyl-3-acetylthiopropanoic acid. Example 6. 2-Ethyl-3-acetylthiopropanoyl chloride. 2-Ethyl-3-acetylthiopropanoic acid (7.88 g) is dissolved in thionyl chloride (6.14 g), the solution is stirred at room temperature for 18 hours. After distillation, 2-ethyl-3-acetylthiopropanoyl chloride is obtained in the form a clear yellow oil, the yield of which is 4.8 g; melting point 50-60 ° C (at a pressure of 0.04 mm Hg). Example 6. 1- (3-Acetylthio-2-ethylpropanoyl) -L-3,4-dehydroproline, L-3,4-dehydroproline (3.4 g) rast, put into 1N sodium hydroxide solution (30 ml) the solution is cooled in a bath with an ice-water mixture. H-acetylthio-2-ethylpropanoyl chloride (5.84 g) and 2N were added to the solution. sodium hydroxide solution (15 ml), the solution is stirred at room temperature for 3 hours. The mixture is extracted with ether, acidified and extracted with ethyl acetate. The organic phase is dried over magnesium sulphate and evaporated to dryness, in which case 1- (3-acetylthio-2-ethylpropanoyl) -L-3,4-dehydroproline is obtained. Example 7. 1- (2-Ethyl-3-mercaptopropanoyl) -1-3,4-dehydroproline. 1- (3-Acetylthio-2-ethylpropanoyl) -L-3, 4-dehydroproline (3 g) is dissolved in a mixture of water (10 ml) and concentrated ammonia solution (10 1 and under nitrogen atmosphere. After 25 minutes, the reaction mixture is acidified and estracted with ethyl acetate. The organic layer is dried over magnesium sulfate and evaporated to dryness, whereby 1- (2-ethyl-3-mercaptopropanoyl) -L-3,4-dehydroproline is obtained. Example 8. 1- (2-Mercaptopropanoyl) -L -3,4-dehydroproline. The proposed compound is prepared analogously to the method described in example 7 using 1- (2-acetylthiopropanoyl) -L-3,4-dehydroproline instead of 1- (3-acetylthio-2-ethylpropanoyl) -L-3,4-dehydroproline, whereby 1- (2-mercaptopropanoyl) -L-3,4-dehydroproline is obtained. Example 9. 1- (3-Acetylthio -2-methylpropanoyl) -O, L-4,5-dehydropiperidin-2-carboxylic acid. 3-Acetylthio-2-methylpropanoyl chloride (5.4 g) and 2N sodium hydroxide solution (15 ml) were added to. a solution of 0.1-4,5-dehydro-piperidine-2-carboxylic acid (4 g) in 1N sodium hydroxide solution (30 ml), cooled in a bath with ice-water mixture. After stirring for 3 hours at room temperature, the mixture is extracted with ether, acidified, and extracted with ethyl acetate. Organically the layer is dried over magnesium sulfate and evaporated to dryness, as a result of which 1- (3-acetylthio-2-methylpropanoyl) -0, 1-4,5-degIdropiperidine-2-carboxylic acid is obtained., Example 10. 1- (3- Mercapto-2-methylpropanoyl) -D, L-4,5-dehydropiperidin-2-carboxylic acid. The process is carried out as described in Example 7, using 1- (3-acetylthio-2-methylpropanoyl) -D, L-4,5-dehydropiperidine-2-carboxylic acid instead of 1- (3-acetylthio-2-ethylpropanoyl) -L -3,4-dehydroproline, whereby 1- (3-mercapto-2-methylpropanoyl) -0, L-4,5-dehydropiperidine-2-carboxylic acid is obtained. Example 11. 1- (3-Mercapto-2-ethylpropanoyl) -D, L-4,5-dehydropiperidine-2-carboxylic acid. Using D, L-4,5-dehydropiperidin-2-carboxylic acid instead of L-3, 4-dehydroproline in the process described in Example 6, and subjecting the product to treatment according to Example 7, 1- (3-mercapto-2- ethylpropanoyl) -0,1-4,5-dehydropiperidine-2-carbonic acid. Example 12. 1- (3-Mercapto-2-methylpropanoyl) -L-3,4-dehydroproline. Using t-3,4-dehydroproline instead of 4,5-dehydropiperidin-2-carboxylic acid, as described in Example 10, and then subjecting the product to the same treatment as described in Example 7, 1- (3-mercapto -2 -methyl (L) 11 panoyl) - L-3, 4-dehydropropols, n. Example 13. The sodium salt of 1- (Z-mercapto-2-methylpropanoyl) -L-3, 4-dehydroproline. A solution of 1- (3-mercapto-2-methylpropanoyl) -L-3,4-dehydroproline in water is neutralized with 1N. With a solution of sodium hydroxide, the water is removed by drying at a temperature below its freezing point, resulting in a sodium salt of 1- (3-mercapto-3-methylpropanoyl) -L-3,4-dehydroproline. Example 14. 1- (3-mercapto-2-methylpropanoyl) -L-3,4-dehydroproprol dicyclohexylammonium salt To a solution of 1- (3-mercapto-2-methyl propanoyl) -L-3,4-dehydroproline in ethyl acetate is added equimolar amount of dicyclohexylamine. The resulting precipitate is separated by centrifugation to obtain 1- (3-mercapto-2-methylpropanoyl) -L-3,4-dehydroproline dicicyclohexyl ammonium salt. Example 15. 1- (3-Acetylthiopropano-IL) -D, L — 3,4-dehydroprol D, L-3,4-Dehydroproline (1.02 g) is dissolved in aqueous 1N. sodium hydroxide solution (9 ml) and cooled in an ice bath. Acetylthiopropionyl chloride (1.5 g in 3 ml of simple ether) is added to this solution and 2 n is gradually added. sodium hydroxide solution (4.8 ml), maintaining a pH of 8.0. The aqueous solution is extracted with ethyl acetate. The pH of this aqueous solution is reduced to 1.5, the injected oil is separated, the aqueous solution is washed with ethyl acetate, and the ethyl acetate extracts are added to the oil. The solvent is removed and the residual product (after elimination of the solvent) is dissolved in a tonitrile (7 ml), dicyclic hexylamine (DSNA) (1.9 ml) is added and then 20 ml of ether. The desired product (dicyclohexylamine salt) is separated in the form of crystals (2.5 g). Melting point 156-158 ° C. Calculated,%: C, 62.38; H 8.33; N 6.61; S 7.57. 22 5 2: ° 4S Found,%: C 62.05-H 8.47 M 6.61; S 7.57. Example 16. 1- (3-Acetylthio propanoyl) -D, L-3,4-dehydroprolin. A mixture of D, L-3,4-dehydroproline (.800 mg), acetylthiopropionic acid, p-nitrophenyl ester (2.45 g) and triethylamine (1.1 in dimethylformamide (30 ml) and water (8L4n) is stirred within 72 the Solvents are removed and the residual product is subjected to chromatographic separation, passing it through silica gel (200 g), using an ethyl acetate – pyridine acetic acid – water system as an eluent of the solvent, in the ratio 60: 20: 6: 11, resulting in 1 , 27 g of the desired product (dicyclohexylamine salt) with a melting point of 156-158 ° C. measures 17. 1- (3-Mercaptopropanoyl) -0.1-3.4-dehydroproline. 1 (3-Acetylthiopropanoyl) -D, L-3, 4-dehydroproline (3.0 g) is dissolved in methanol 5.5. ammonia solution (15 ml) and kept at room temperature for 45 minutes, the solvent is removed, the remaining product is dissolved in water, passed through AG-50 resin, lyophilized and subjected to chromatographic separation by passing through silica gel (50 g), using as a solvent the system: benzene-acetic acid in a ratio of 8: 2, resulting in a gain of 0.8 g of the target product with a temperature 161-163 ° C (sintering at 143s) as a dicyclohexylamine salt. Calculated,%: C, 47.74; H, 5.51N; 6.96; S 15.93; Found: C 48.09; H 5.73; N 6.86; S 15.65. Example 18. 1- (D-3-acetylthio-2-methylpropanoyl) -D, L-3,4-dehydroproline. D, L-3,4-dehydroproline (3.38 g) was dissolved in an aqueous solution of sodium carbonate and cooled in an ice bath. P-Acetylthio-2-methylpropionyl chloride was added to this solution in two portions (5.5 g in 10 ml of ether) and then 4N sodium carbonate solution (16 ml) over 15 minutes, maintaining the pH at about 7 ,five. The solution is then stirred for 1 hour, extracted with ethyl acetate, acidified to pH 2.0, saturated with sodium chloride and extracted with ethyl acetate. The ethyl acetate extract is evaporated, the resulting product is passed through a column filled with silica gel (300 g) and eluted with benzene-acetic acid solvent in a ratio of 10:
    [2]
    2. Output 5.7 g: oLj2F 69.1 (s 2, SNZON). Rf 0,34 (silica gel and. Eluting solvent benzene - acetic acid in the ratio 7: 2). Calculated,%: C 4.99H 6.22N 5.09} S 11.59 L-H 5-N04S.H20 Found,%: C 48.20; H 6.29; N 4.91; S 11.34. Example 19. 1- (0-3- (Acetylthio- (2-methylpropanoyl) -1-3,4-degylproproline. To a stirred solution of the product obtained in Example 22 in acetonitrile (4.7 g in 100 ml) of a forehead, 1 ml of dicyclohexylamine was added, the solution was kept cold overnight, and the precipitated crystals were filtered and recrystallized from acetonitrile. 2.8 g yield as dicyclohexylamine salt. CdJl-222 (c 2, CHOH), melting point 188-190 ° C. This dicyclohexylamine salt (2.7 g) is dissolved in 25 ml of water, treated with AG-50 (H) resin with a bed volume of 90 ml and filtered. washed thoroughly with water (200 ml), methanol-water 1: 1 (100 ml), and methanol (200 ml). The washing solvents are combined and evaporated to dryness. Yield 1.45 g Ca (-326 (1) , SNZON.) RI 0.36 (silica gel, eluting with benzene-acetic acid solvent in a ratio of 7: 2). Calculated,%: C 51.35; H 5.88; N 5.44; - S 12.46 C. Found:% C 51, 30j H 6.20; N 5.43; S 12.16. Example 20. 1- (D-3-Packaging -2 -2-methylpropanoyl) -L-3,4-dehydroproline ( right rotational form). The product obtained in Example 13 (1.2 g) was dissolved in methanol (10 ml), and to this solution an aqueous 13.5 n was added under argon atmosphere. ammonium hydroxide solution (8 ml of iPacTBOp is kept at room temperature for 35 minutes, evaporated, dissolved, 20 ml of water is added, acidified to pH 1.5 and extracted with ethyl acetate. The ethyl acetate extract is evaporated. The yield is 629 mg with temperature melting 121-124 s (sintering at). d3 -352 °; (s 1.2, СНЗОН). Calculated,%: C 50.22; H 6.09; N 6.51; S 14.89 C, H ., N O S S Found,%: C 49.93; H 5.84; N 6.28; S 14.87. Example 21. 1- (D-3-Acetylthio-2-methylpropionyl) -4.5- dehydropipecololinic acid. To an ice-cooled solution of L-4, 5-dehydropipecololinic acid (290 mg) in an aqueous 1N solution of carbon This sodium (2.3 ml) is added with 0-3-acetylthio-2-methylpropionyl chloride (0.332 g) in 1 ml of ether (the pH is kept at about 7.5, while 1.1 ml of 2 n taragCO are consumed for 3 h. The reaction mixture is extracted with ether, acidified to a pH of 2.0 and extracted with ethyl acetate. The ethyl acetate extract is chromatographed by passing it through silica gel (10 g using the solvent system: benzene-acetic acid in the ratio 10: 1. Yield 12 mg of the desired product in the form of a homogeneous oil. R 0.32, adsorbent - silica gel, eluting solvent benzene - acetic acid in the ratio 10: 1. Example 22. 1- (0-3-Mercapto-2-methylpropionyl) -4,5-dehydropipekolinic acid. A solution of 1- (0-3-acetylthio-2 methylpropionyl) -4, 5 dehydropipecolonic acid (91 mg) in methanolic 5.5 n. the ammonia solution (0.5 lp) was kept at room temperature under argon for 30 minutes, the solvent was distilled off, the residual product was dissolved in water, acidified to a pH of 2.0, and extracted with ethyl acetate. The ethyl acetate extract is evaporated. Melting point 150-152s (sintering at). Yield 74 g of dicyclohexylamine salt. Rr 0.32 adsorbent (with chromatographic separation) - silica gel, benzene-acetic acid eluting solvent system (10: 1 ratio). The method of obtaining the dehydrocyclic imino acid derivatives of the general formula I R, HeC-CH RrS-1CHi) n-CH-C-H. (CHi) m Rj means each of the R groups and a hydrogen atom or low alkyl; R is a hydrogen atom, a lower alkanoyl; The type is O or 1, characterized in that the compound of formula I. Ri-S- (CHt) n-CH-COOH, RJ - lower alkanryl. they are reacted with the coupling of the general Formula III H "of ™ I COOR de R-values given above, in the presence of a carbodiimide, for example icyclohexylcarbodiimyl; or a ganoid anhydride or anhydride of an acid of a common formula II is interoperated; 86069712
    action with a common form connection - Sources of information,
    ly III, and the resulting target njpo-taken into account in the examination
    The product is either isolated or subjected. .
    hydrolysis, and then isolate cele-1-Houben - Weyl. Methoden der
    A product in which RI is an atom in-Organischem Chemle. Stuttgard 1974
    prenatal. 1 35, h. 2, sl.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU860697A1|1981-08-30|Method of preparing derivatives of dehydrocyclic iminoacids
    EP0172458B1|1989-11-02|Novel biologically active compound having anti-prolyl endopeptidase activity
    DE2801911C2|1991-03-21|
    DE2703828C2|1984-06-20|Proline derivatives and similar compounds and their use in combating high blood pressure
    DE2932021C2|1994-05-19|1- | - | -thio-L-proline derivatives, their preparation and their use in the treatment of hypertension
    US4086338A|1978-04-25|N-carboxyalkanoyl derivatives of azetidine-2-carboxylic acid
    US4046889A|1977-09-06|Azetidine-2-carboxylic acid derivatives
    EP0184550B1|1992-03-18|5-amino-4-hydroxy valeryl amide derivatives
    US4772587A|1988-09-20|Dipeptide derivative of fatty acid
    US4192945A|1980-03-11|Process for preparing proline and homoproline derivatives
    US4154937A|1979-05-15|Hydroxycarbamoylalkylacylpipecolic acid compounds
    US4320057A|1982-03-16|Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
    DE2946909A1|1981-06-04|NEW TETRAHYDROISOCHINOLINE DERIVATIVES
    CH645092A5|1984-09-14|MERCAPTOACYL PEPTIDES AND MEDICINAL PRODUCTS CONTAINING THEM.
    US4296033A|1981-10-20|4-Azido-1-mercaptoacyl proline
    CH643268A5|1984-05-30|Pyrrolo OR pyrido | | OR thiazines -THIAZEPINE.
    DE3113610A1|1982-04-22|S-ACYLATION PRODUCTS OF A MERCAPTOACYLAMINO ACID AND A DIURETIC CONTAINING A CARBOXYL GROUP
    DE3334739A1|1984-03-29|ACYLOXYKETONE SUBSTITUTED IMINO AND AMINO ACIDS AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
    US4290952A|1981-09-22|Aryl-1-mercaptoalkanoylproline and homoproline derivatives
    SU1470189A3|1989-03-30|Method of producing derivatives of interfuranyleneprostacyclins
    EP0059966B1|1986-08-13|Substituted thiazolidine carboxylic acid analogs and derivatives as antihypertensives
    US4709046A|1987-11-24|Acylmercaptoalkanoyl and mercaptoalkanoyl spiro compounds
    AT371435B|1983-06-27|METHOD FOR PRODUCING NEW ALKYLENE IMIN DERIVATIVES AND THEIR SALTS
    US4308388A|1981-12-29|4-Azido-1-mercaptoacyl pipecolic acid
    EP0125106B1|1986-09-17|1-acylamino-1-cyclopentanecarboxylic acids and a process for preparing them
    同族专利:
    公开号 | 公开日
    AR222481A1|1981-05-29|
    ES477695A1|1979-10-16|
    NL7901197A|1979-08-17|
    HU178115B|1982-03-28|
    DE2904823A1|1979-08-16|
    IN151091B|1983-02-19|
    BE874202A|1979-08-16|
    FI790502A|1979-08-16|
    PT69224A|1979-03-01|
    IE48072B1|1984-09-19|
    ZA79483B|1980-03-26|
    FR2417500A1|1979-09-14|
    FI67369C|1985-03-11|
    LU80925A1|1979-06-18|
    IL56606D0|1979-05-31|
    US4129566A|1978-12-12|
    DD141670A5|1980-05-14|
    PL213449A1|1979-12-03|
    PH14730A|1981-11-19|
    AT375919B|1984-09-25|
    HK35882A|1982-08-20|
    NZ189574A|1981-05-15|
    PL116509B1|1981-06-30|
    NO790495L|1979-08-16|
    RO76614A|1981-04-30|
    ATA118879A|1984-02-15|
    IT1113713B|1986-01-20|
    JPS643870B2|1989-01-23|
    US4154942A|1979-05-15|
    FR2417500B1|1982-10-22|
    DK63479A|1979-08-16|
    US4156084A|1979-05-22|
    GB2014573B|1982-05-06|
    EG13875A|1982-09-30|
    GR74445B|1984-06-28|
    NO153054B|1985-09-30|
    FI67369B|1984-11-30|
    CS213370B2|1982-04-09|
    AU4400679A|1979-08-23|
    IT7947986D0|1979-02-13|
    GB2014573A|1979-08-30|
    AU520475B2|1982-02-04|
    CH636608A5|1983-06-15|
    CA1124725A|1982-06-01|
    NO153054C|1986-01-08|
    JPS54125683A|1979-09-29|
    IE790292L|1979-08-15|
    YU36379A|1983-04-30|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3531490A|1968-09-06|1970-09-29|Us Agriculture|S-beta--l-cysteine|
    US3917815A|1969-09-04|1975-11-04|Oreal|Cosmetic compositions containing N-oxypyridyl derivatives|
    US4066658A|1975-08-11|1978-01-03|Hoffmann-La Roche Inc.|Resolution of d,l-dehydroproline|
    AU509899B2|1976-02-13|1980-05-29|E.R. Squibb & Sons, Inc.|Proline derivatives and related compounds|
    US4046889A|1976-02-13|1977-09-06|E. R. Squibb & Sons, Inc.|Azetidine-2-carboxylic acid derivatives|
    US4105776A|1976-06-21|1978-08-08|E. R. Squibb & Sons, Inc.|Proline derivatives and related compounds|ZA794723B|1978-09-11|1980-08-27|Univ Miami|Anti-hypertensive agents|
    US4198515A|1978-12-08|1980-04-15|E. R. Squibb & Sons, Inc.|Mercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids|
    US4217458A|1978-12-08|1980-08-12|E. R. Squibb & Sons, Inc.|Acylmercaptoacyl derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids|
    US4220791A|1979-03-08|1980-09-02|E. R. Squibb & Sons, Inc.|Mercaptoacylpyrazolidinone carboxylic acid derivatives|
    US4211786A|1979-03-08|1980-07-08|E. R. Squibb & Sons, Inc.|Mercaptoacyldihydropyrazole carboxylic acid derivatives|
    FR2455585A1|1979-05-04|1980-11-28|Ono Pharmaceutical Co|OXOAMINOACID DERIVATIVES, MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION|
    US4234489A|1979-06-25|1980-11-18|E. R. Squibb & Sons, Inc.|Pyroglutamic acid derivatives and analogs|
    US4695577A|1979-08-14|1987-09-22|University Of Miami|Anti-hypertensive agents|
    US4690940A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4698355A|1979-08-14|1987-10-06|University Of Miami|Anti-hypertensive agents|
    US4690938A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4690937A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4690939A|1979-08-14|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4698356A|1979-08-14|1987-10-06|University Of Miami|Anti-hypertensive agents|
    US4221912A|1979-08-22|1980-09-09|E. R. Squibb & Sons, Inc.|Dithio derivatives of 4,5-dihydro-1H-pyrrole-2-carboxylic acids and 1,4,5,6-tetrahydropyridine-2-carboxylic acids|
    US4221804A|1979-09-27|1980-09-09|Rovnyak George C|Mercaptoacyldihydropyrazole carboxylic acid derivatives|
    US4356182A|1979-10-22|1982-10-26|E. R. Squibb & Sons, Inc.|Mercaptoacyl derivatives of 4-disubstituted prolines|
    US4291040A|1979-10-22|1981-09-22|E. R. Squibb & Sons, Inc.|Mercaptoacyl derivatives of 4-disubstituted prolines and 4-substituted dehydroprolines|
    US4499287A|1981-02-02|1985-02-12|E. R. Squibb & Sons, Inc.|Certain-4-hydroxy-proline derivatives|
    US4456761A|1981-02-02|1984-06-26|E. R. Squibb & Sons, Inc.|4-Substituted dehydroprolines|
    US4308392A|1979-12-03|1981-12-29|E. R. Squibb & Sons, Inc.|Hydroxamic acid derivatives of mercaptoacyl amino acids|
    US4284561A|1979-12-03|1981-08-18|E. R. Squibb & Sons, Inc.|Hydroxamic acid derivatives of mercaptoacyl amino acids|
    IE50839B1|1980-02-26|1986-07-23|Wyeth John & Brother Ltd|Novel processes for preparing proline derivatives and analogous compounds|
    US4692458A|1980-03-05|1987-09-08|University Of Miami|Anti-hypertensive agents|
    US4690936A|1980-03-05|1987-09-01|University Of Miami|Anti-hypertensive agents|
    US4734420A|1980-03-05|1988-03-29|University Of Miami|Anti-hypertensive agents|
    US4266065A|1980-04-14|1981-05-05|E. R. Squibb & Sons, Inc.|Mercaptoacyldihydropyrazole carboxylic acid derivatives|
    US4284624A|1980-05-02|1981-08-18|E. R. Squibb & Sons, Inc.|Mixed disulfides|
    US4310461A|1980-06-23|1982-01-12|E. R. Squibb & Sons, Inc.|Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids|
    US4344949A|1980-10-03|1982-08-17|Warner-Lambert Company|Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids|
    US4532342A|1981-02-20|1985-07-30|Warner-Lambert Company|N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids|
    US4350704A|1980-10-06|1982-09-21|Warner-Lambert Company|Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids|
    US4374131A|1981-04-27|1983-02-15|E. R. Squibb & Sons, Inc.|Amino and substituted amino phosphinyl-alkanoyl compounds|
    US4416831A|1981-04-27|1983-11-22|E. R. Squibb & Sons, Inc.|Amino and substituted amino phosphinylalkanoyl compounds|
    US4381297A|1981-05-04|1983-04-26|E. R. Squibb & Sons, Inc.|Substituted carbonyl phosphinyl-alkanoyl compounds|
    US4416833A|1981-05-04|1983-11-22|E. R. Squibb & Sons, Inc.|Substituted carbonyl phosphinyl-alkanoyl compounds|
    US4432971A|1981-08-03|1984-02-21|E. R. Squibb & Sons, Inc.|Phosphonamidate compounds|
    US4503043A|1981-12-07|1985-03-05|Warner-Lambert Company|Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids|
    US4555506A|1981-12-24|1985-11-26|E. R. Squibb & Sons, Inc.|Phosphorus containing compounds and use as hypotensives|
    US4560680A|1982-03-15|1985-12-24|E. R. Squibb & Sons, Inc.|Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors|
    US4452791A|1982-03-15|1984-06-05|E. R. Squibb & Sons, Inc.|Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors|
    US4448772A|1982-04-22|1984-05-15|E. R. Squibb & Sons, Inc.|Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension|
    US4560681A|1982-04-22|1985-12-24|E. R. Squibb & Sons, Inc.|Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension|
    US4452790A|1982-06-23|1984-06-05|E. R. Squibb & Sons, Inc.|Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives|
    US4616005A|1982-06-23|1986-10-07|E. R. Squibb & Sons, Inc.|Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives|
    US4703043A|1982-06-23|1987-10-27|E. R. Squibb & Sons, Inc.|Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive|
    US4567166A|1982-07-14|1986-01-28|E. R. Squibb & Sons, Inc.|Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension|
    US4470973A|1982-07-19|1984-09-11|E. R. Squibb & Sons, Inc.|Substituted peptide compounds|
    US4736066A|1982-07-19|1988-04-05|E. R. Squibb & Sons, Inc.|Intermediate for substituted peptide compounds|
    US4621092A|1982-07-22|1986-11-04|E. R. Squibb & Sons, Inc.|Substituted proline compounds, composition and method of use|
    US4742067A|1982-07-22|1988-05-03|E. R. Squibb & Sons, Inc.|Acylalkylaminocarbonyl substituted amino and imino acid compounds|
    US4623729A|1982-07-22|1986-11-18|E. R. Squibb & Sons, Inc.|Acylalkylaminocarbonyl substituted amino and imino acid compounds|
    US4524212A|1982-09-27|1985-06-18|E. R. Squibb & Sons, Inc.|Acyloxyketone substituted imino and amino acids|
    US4514391A|1983-07-21|1985-04-30|E. R. Squibb & Sons, Inc.|Hydroxy substituted peptide compounds|
    CA2021409A1|1989-08-21|1991-02-22|Donald S. Karanewsky|Phosphonate substituted amino or imino acids useful as antihypertensives|
    GB9016476D0|1990-07-27|1990-09-12|Sandoz Ltd|Improvements in or relating to organic compounds|
    JP2002541094A|1999-04-01|2002-12-03|アルザ・コーポレーション|Transdermal drug delivery device comprising a polyurethane drug reservoir|
    WO2016032008A1|2014-08-29|2016-03-03|京セラ株式会社|Sensor device and sensing method|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/878,144|US4129566A|1978-02-15|1978-02-15|Derivatives of dehydrocyclicimino acids|
    [返回顶部]